Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Early HER2-positive breast cancer, drawn from the whole corpus: 23 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Which women can skip chemotherapy entirely without losing cure.
Interstitial lung disease from trastuzumab deruxtecan in women who would otherwise have been cured.
Hormone receptor-positive HER2-positive tumours respond less and the right endocrine and HER2 maintenance is unsettled.
Cardiac safety of longer and stronger HER2 regimens over decades of survivorship.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 23 changes by month →When this page itself was last checked or edited.
3-year iDFS 92.
pCR 67.
A milestone in how this cancer is treated.
3-year iDFS 95.
A milestone in how this cancer is treated.